Lineage Cell Therapeutics, Inc.LCTXNYSE
Loading
Cash & Equivalents Over TimeContracting
Percentile Rank79
3Y CAGR+53.2%
5Y CAGR+4.6%
Studio
Year-over-Year Change

Cash on hand plus short-term liquid investments

3Y CAGR
+53.2%/yr
vs -16.7%/yr prior
5Y CAGR
+4.6%/yr
Recent acceleration
Acceleration
+69.9pp
Accelerating
Percentile
P79
Within normal range
vs 5Y Ago
1.3x
Solid growth
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$40.79M-10.9%
2024$45.79M+29.2%
2023$35.44M+212.1%
2022$11.36M-79.6%
2021$55.74M+71.1%
2020$32.59M+243.1%
2019$9.50M-59.7%
2018$23.59M-36.0%
2017$36.84M+66.8%
2016$22.09M-